Quoin Pharmaceuticals (QNRX) Free Cash Flow (2021 - 2026)

Quoin Pharmaceuticals has reported Free Cash Flow for 6 years, with the latest figure at -$4.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 87.69% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.8 million (down 75.4% YoY) and the FY2025 annual result came in at -$13.5 million, down 72.34% from the prior year.
• Free Cash Flow advanced to -$4.9 million in Q1 2026 per QNRX's latest filing, from -$5.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.3 million in Q3 2023 and troughed at -$5.0 million in Q4 2025.
• A 5-year average of -$2.5 million and a median of -$2.2 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 152.71% in 2022, then surged 42.38% in 2023.
• Over 5 years, Free Cash Flow stood at -$1.9 million in 2022, then slumped by 65.97% to -$3.2 million in 2023, then surged by 30.62% to -$2.2 million in 2024, then sank by 125.13% to -$5.0 million in 2025, then gained by 3.3% to -$4.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$4.9 million, -$5.0 million, and -$2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.